At a recent memorial service for conservative political activist Charlie Kirk in Glendale, Arizona, President Donald Trump used his platform to hint at a significant upcoming announcement related to autism. During his eulogy on September 21, 2025, Trump spoke about finding an “answer to autism” and vowed that his administration would not allow the condition to persist unchecked. He described the impending news as one of the most significant medical announcements in the history of the United States.
:max_bytes(150000):strip_icc():format(jpeg)/donald-trump-charlie-kirk-memorial-glendale-092225-e7ba78c567d845739475927a4bc4f591.jpg)
Accompanying Trump in this anticipated revelation is his Health and Human Services Secretary, Robert F. Kennedy Jr., who is scheduled to make the announcement on September 22nd. The focus of their announcement is reported to be a potential link between autism and the use of Tylenol during pregnancy. Despite existing research spanning over a decade that negates any correlation between the two, and contrary to established medical guidelines, the Trump administration is poised to present a different perspective, as reported by The Washington Post.
Sources cited by the Post indicate that the administration may suggest that acetaminophen, found in Tylenol, could pose risks to pregnant women. However, neither the White House nor the U.S. Department of Health and Human Services responded immediately for comment when contacted by PEOPLE. The potential connection between using the medication in early pregnancy and a heightened risk of autism in children has been highlighted in recent studies, including a review by researchers from Harvard University and Mount Sinai Hospital.
Politico reported insights from two senior administration officials, indicating that women may be advised to restrict the use of Tylenol or generic acetaminophen during pregnancy to instances of high fever only. White House spokesperson Kush Desai hinted at the forthcoming announcement representing a significant step forward in history. This development follows Kennedy’s pledge made earlier this year, during a cabinet meeting with Trump in April, where he assured the revelation of autism’s causal factors by September.
In response to the brewing controversy, Kenvue, the parent company of Tylenol, defended the safety of acetaminophen usage in pregnancy. They expressed confidence in scientific evidence supporting the safety of the medication and refuted any suggestion of a link to autism. The company stressed the importance of providing pregnant women with safe pain relief options, emphasizing the absence of conclusive evidence connecting acetaminophen to the developmental disorder.
Autism, or autism spectrum disorder, is a neurodevelopmental condition that can impact various aspects of an individual’s life, including social interaction, communication challenges, and repetitive behaviours. Mayo Clinic describes it as a condition that affects brain development and manifests in diverse ways. Despite ongoing debates and conflicting viewpoints on the potential causes of autism, the medical community generally acknowledges the complexity of the disorder’s origins.
As the public awaits the official announcement from Trump and Kennedy regarding autism and Tylenol, the debate surrounding the condition’s causes continues to evolve. With diverging perspectives on the table, the impact of such proclamations may have far-reaching implications for expectant mothers and individuals living with autism. The intersection of political figures making medical assertions underscores the need for thorough research and collaboration between experts to address complex healthcare issues like autism comprehensively.
The forthcoming announcement on autism and Tylenol usage during pregnancy is poised to trigger further debate and scrutiny within the medical community and beyond. As the narrative unfolds, the implications of such claims on public health policies, medical practices, and individual decision-making come to the forefront. The intersection of politics and healthcare underscores the importance of evidence-based research, transparent communication, and collaborative efforts to navigate intricate healthcare challenges such as autism effectively.